MicroID2: Streamlined for better biotinylation
The study of protein interactions is a big field in molecular biology. Proteins network with one another for both intercellular and extracellular signaling pathways, many of which require the relevant proteins to be close together.
Researchers often use proximity-dependent biotinylation to characterize these interactions. In this process, an enzyme that labels proteins with biotin is attached to a protein of interest using CRISPR-based or plasmid-based expression strategies. When biotin is added to the experimental system, any protein in close proximity to the protein of interest is tagged and researchers then can purify and identify it.

Proximity-dependent biotinylation recently was used to discover sites where mitochondria contact the endoplasmic reticulum. The outer mitochondrial membrane is difficult to map by purification; the process quickly destroys the membrane, and membrane enrichment techniques are not perfect. By using biotinylation, researchers in the Ting lab at Stanford University proteins on the outer mitochondrial and endoplasmic reticulum membranes of living human cells.
’s lab at the Ohio State University Wexner Medical Center in Columbus, Ohio, has modified the structure of a state-of-the-art proximity-dependent biotinylation protein, BioID2,that is derived from Aquifex aeolicus bacteria. Benjamin Johnson, a graduate student and first author of in the journal Molecular & Cellular Proteomics,explained that by removing the C-terminus of BioID2, the Londino lab created MicroID2, a smaller biotin ligase with fewer nonspecific labeling events than its predecessors.
“We asked, ‘Do we need this entire construct in order to facilitate labeling?’” Londino said.
The size of the ligase matters because larger constructs can cause mislocalization of the protein and disruption of endogenous signaling. This means the host cell will not perform its signaling pathways and other reactions as it would without the insertion of this new protein, skewing the validity of any results. A too-large construct may appear to associate with proteins in artificial ways.
The biotin ligase has a minimum size limit, however. Truncation of the BioID2 C-terminus beyond 63 amino acids completely inactivated the biotinylation activity. Deletion of 10 amino acids from the N-terminus also inactivated the enzyme.
The researchers performed other mutations to develop MicroID2, including substitutions at the active site, that increased the labeling efficiency. Additional mutations reduced nonspecific labeling, allowing more accurate analysis of protein–protein interactions.. Additional mutations reduced nonspecific labeling, allowing more accurate analysis of protein–protein interactions.
“When we’re overexpressing these constructs, they’re going to be continuously labeling,” Londino said. “Even when we completely deplete biotin from the media, there’s still going to be a certain amount of biotin labeling that occurs. By reducing the ability of these constructs to scavenge biotin … we were able to reduce the overall amount of background labeling.”
Johnson described MicroID2 as the smallest biotin ligase yet developed that maintains a high level of activity, but the lab is not done optimizing the construct. Next steps include further exploration of stable integration of the ligase and optimization of its stability.
The Londino lab plans to use these constructs to examine how ubiquitin ligases target specific proteins for degradation. As a lab studying ubiquitin biology, “we are pretty well positioned” to use this tool to examine protein stability, Johnson said.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Mapping the placenta鈥檚 hormone network
Study uncovers how the placenta actively metabolizes not only glucocorticoids but also novel androgens and progesterones, reshaping our understanding of pregnancy and its complications.

Biochemists and molecular biologists sweep major 2025 honors
Recent Nobel, MacArthur and Kimberly Prize honorees highlight the power of biochemistry and molecular biology to drive discovery, including immune tolerance, vaccine design and metabolic disease, and to advance medicine and improve human health.

Spider-like proteins spin defenses to control immunity
Researchers from Utrecht University discovered two distinct binding modes of a spider-shaped immune inhibitor found in serum.

A biological camera: How AI is transforming retinal imaging
AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Antibiotic resistance kills millions, but César de la Fuente鈥檚 lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.